Market access is value contextual, thus using RWE to secure appropriate market access allows evidence to reflect effectiveness in the real world where protocols may not be followed, patients don’t take their medications, and where every population is viewed as unique requiring data to reflect that specific population . This presentation walks through the reality of developing RWE for an EUmarketed, post-anaesthesia medication using a retrospective observational study format and demonstrates the importance of thinking carefully about your strategy (the benefits, risks, costs and mitigations) before embarking.
Mervyn D. Hall
Director of Market Access – Europe
Truven Health Analytics, UK
This is the presenters’ personal opinion and does not necessarily represent true facts, the official views or policy of their organisation, nor the views of NextLevel Life Sciences.